Michael Farwell, MD, associate professor of radiology at the Hospital of the University of Pennsylvania, provides insights into a study on the benefits of using 18F-fluorodeoxyglucose (FDG) PET/CT ...

Predictors of response to neoadjuvant chemotherapy in estrogen receptor-positive breast cancer. This is an ASCO Meeting Abstract from the 2015 ASCO Annual Meeting I. This abstract does not include a ...

Expert Rev Anticancer Ther. 2009;9(1):75-96. Based on the available data, FDG-PET alone appears to be of limited use in differentiating tumors of low malignant potential from benign tumors and ovarian ...

A new Journal of Clinical Oncology report immediately informs practicing clinicians of the effectiveness and benefits of FDG-PET/CT in head and neck cancer patients, especially those who are ...

18 F-FDG-PET/CT (F-FDG) appears to offer value for staging of cutaneous squamous cell carcinoma (cSCC), according to the results of a recent small, single-institution study. 1 F-FDG reliably detected ...

Staging locally advanced breast cancer patients with 18 F-labeled fluorodeoxyglucose (FDG) PET-CT detected more distant metastases -- and thus reduced the number of patients who received combined ...

Comparing Paclitaxel Plus Fluorouracil Versus Cisplatin Plus Fluorouracil in Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Cancer: A Randomized, Multicenter, Phase III Clinical Trial ...

Fluorodeoxyglucose (FDG) has proven benefits as a positron emission tomography (PET) radiopharmaceutical in oncology. However, it has limitations in the assessment of certain tumours, above all (but ...

The Journal of Clinical Oncology has published the results of the largest prospective multicenter trial conducted of FDG-PET/CT in head and neck cancer, providing rigorous data about its performance.